BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has expanded its scientific advisory board (SAB) with the appointment of two new members: Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center; and Christopher Sturgeon, Ph.D., associate professor at the Icahn School of Medicine at Mount Sinai.
As leaders in the study of natural killer (NK) cell biology, the development of NK cell therapies for the treatment of cancer, and the differentiation of induced pluripotent stem cells (iPSCs), Drs. Rezvani and Sturgeon will bring experience and insights that will be invaluable to Caribou as we develop genome-edited NK cell therapies derived from iPSCs using our proprietary next-generation chRDNA platform, said Steven Kanner, Ph.D., Caribous chief scientific officer. We are excited to welcome these renowned experts to our SAB and work with them as we advance our pipeline of potentially best-in-class genome-edited allogeneic CAR-T and CAR-NK cell therapies for cancer patient treatment.
The opportunity to carry out multiple high specificity genome edits with Caribous chRDNA platform in iPSCs followed by their differentiation into NK cells holds the promise of safer and more effective allogeneic cell therapies with broad therapeutic potential, said Dr. Sturgeon. I look forward to working with the Caribou team to help translate known iPSC and NK cell biology into effective therapies and potentially implement this therapeutic approach more widely for patients with solid tumors and metastases.
Dr. Rezvani is the Sally Cooper Murray Chair in Cancer Research, chief of the Section for Cellular Therapy, director of Translational Research, and director of the GMP Facility at MD Anderson. She also serves as executive director of MD Andersons Adoptive Cell Therapy Platform. Her laboratory focuses on the role of NK cells in mediating immunity against hematologic and solid tumors in order to understand mechanisms of tumor-induced NK cell dysfunction and to develop strategies to genetically engineer NK cells to enhance their in vivo anti-tumor activity and persistence. Findings from Dr. Rezvanis lab have led to the funding of several investigator-initiated clinical trials of NK cell immunotherapies in patients with hematologic malignancies and solid tumors, as well as the first-in-human clinical trial of off-the-shelf CAR-transduced cord blood-derived NK cells in patients with relapsed/refractory lymphoid malignancies. Dr. Rezvani completed her medical training at University College London, followed by fellowships from the Royal College of Physicians and the Royal College of Pathologists of the United Kingdom, a Ph.D. in Immunology from Imperial College London, and postdoctoral studies at the National Institutes of Health.
Dr. Sturgeon is an associate professor at the Icahn School of Medicine at Mount Sinai. His studies focus on characterizing the signal pathways that control human pluripotent stem cell differentiation towards hematopoietic stem/progenitors and how this impacts NK cell development and function. Prior to joining Mount Sinai, Dr. Sturgeon was a member of the Washington University School of Medicine Hematology Division. He received a Ph.D. in Biochemistry on cell cycle regulation at the University of British Columbia. Dr. Sturgeon completed postdoctoral studies at the McEwen Centre for Regenerative Medicine at the University of Toronto where he studied pluripotent stem cell-derived hematopoiesis.
Disclosures
Dr. Rezvani receives compensation as a member of Caribous SAB (as do the other SAB members), and this financial relationship has been disclosed to MD Andersons Conflict of Interest Committee in accordance with institutional policy.
About Caribous Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to editing at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function. In response to this challenge, Caribou has developed chRDNAs (pronounced chardonnays), RNA-DNA hybrid guides that direct substantially more precise genome editing, including multiplex editing and gene insertion, than all-RNA guides. Caribou is deploying the power of chRDNAs to develop CRISPR-edited therapies by guiding cellular editing with the highest level of fidelity.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the companys proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies with best-in-class potential. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors for clinically validated targets as well as new targets.
For more information about Caribou, visit http://www.cariboubio.com and follow the company @CaribouBio.
Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
Read the original post:
- From Cord Blood to Microbiome; The evolution of Rotary's gift to the people of WA - Lifeblood - May 2nd, 2024
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune ... - Nature.com - April 28th, 2024
- Hitting the pavement for cord blood research | Cranbourne Star News - Cranbourne Star News - April 28th, 2024
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
- Cord blood banking comes at a high cost to babies - STAT - STAT - January 18th, 2024
- Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances - PR Newswire - January 16th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 11th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 4th, 2024
- askST: Can cord blood units be transferred from one bank to another? - The Straits Times - December 27th, 2023
- Timeline: Cordlife's mishandling of cord blood units in Singapore - CNA - December 15th, 2023
- Next-Level Evolution: Enhancing the Human Body With Anthrobots ... - Securities.io - December 5th, 2023
- Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ... - Fred Hutchinson Cancer Center - December 5th, 2023
- Enhancing the immunosuppressive properties of human umbilical ... - Phys.org - December 1st, 2023
- Global Status and Trends for Thromboangiitis Obliterans | JPR - Dove Medical Press - December 1st, 2023
- Early Stage Cell Therapy Trial Shows Promise in Treating Progressive Multiple Sclerosis - University of Colorado Anschutz Medical Campus - December 1st, 2023
- Global Medical Specialty Bag Market is Expected to Reach US$ 9.4 Billion by 2034, Rising at a Steady 4.7% CAGR | Future Market Insights, Inc. - Yahoo... - November 29th, 2023
- Repeated concussions can alter heart activity and impact the heart ... - Philippine Canadian Inquirer - November 29th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - PharmiWeb.com - November 27th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - Marketscreener.com - November 25th, 2023
- FY 2021 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- New study aims to expand access to stem cell transplant using ... - Healio - November 23rd, 2023
- Impact of GVHD Prophylaxis on CMV Reactivation and Disease ... - Cancer Network - November 23rd, 2023
- The Top 25 Women Leaders in Biotechnology of 2023 - The Healthcare Technology Report. - November 21st, 2023
- First Edition: November 20, 2023 - KFF Health News - November 21st, 2023
- An essential guide to the building blocks of life - Gates Notes - November 21st, 2023
- A Simple Way to Save Premature Babies - The New York Times - November 19th, 2023
- Perspectives of current understanding and therapeutics of Diamond ... - Nature.com - November 17th, 2023
- Brain Organoids: Should They Be Considered People? - BBVA OpenMind - November 17th, 2023
- Understanding the cause of childhood Alzheimer's - ASBMB Today - November 17th, 2023
- Peripheral nerve regeneration through nanofiber scaffolds | IJN - Dove Medical Press - November 15th, 2023
- Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail - November 13th, 2023
- CAR-NK: The next generation in hematological malignancy treatment - News-Medical.Net - November 13th, 2023
- Regenerative Medicine | Top Regenerative Medicine Solution ... - Healthcare Tech Outlook - November 13th, 2023
- Stem cell therapy, emerging solution to slow down ageing - Punch Newspapers - November 13th, 2023
- Improving Cord Blood Transplantation Outcomes for Adults With ... - On Cancer - Memorial Sloan Kettering - November 11th, 2023
- 8 Ways To Save Lives With Canadian Blood Services & You Can ... - Narcity Canada - November 11th, 2023
- Internal investigation by Vita 34 AG reveals irregularities related to a ... - Marketscreener.com - November 11th, 2023
- 'We worried the worst would happen' - Yorkshire Children's Trust ... - The Yorkshire Post - November 11th, 2023
- Minor GPI(-) granulocyte populations in aplastic anemia and healthy ... - Nature.com - November 9th, 2023
- Repeated treatment with ProTrans is immunologically safe ... - Marketscreener.com - November 7th, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells - Benzinga - November 7th, 2023
- Health Canada issues warning on cord blood stored in Edmonton - CBC News - November 3rd, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Yahoo... - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance ... - InvestorsObserver - November 3rd, 2023
- Go with the flow and achieve hearing restoration - Drug Discovery News - November 3rd, 2023
- Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report - November 1st, 2023
- Cross-talk between Myeloid and B Cells Shapes the Distinct ... - Cancer Discovery - November 1st, 2023
- Comparison of effects of HucMSCs, exosomes, and conditioned ... - Nature.com - October 28th, 2023
- The structural and functional complexity of the integrative ... - Science - October 28th, 2023
- Global Primary Cells Market to Witness Growth at 11.41% CAGR to ... - GlobeNewswire - October 26th, 2023
- Hma-Qubec celebrates 25 years of giving life in anniversary ad - - The Message - October 26th, 2023
- Improvement of thermal-stability of chondroitinase ABCI immobilized ... - Nature.com - October 26th, 2023
- Sydney Couple Overcomes Sperm Antibody Issue to Welcome Baby - OPP.Today - October 24th, 2023
- New Research Reveals Surprising Issue with Sperm and Fertility - CityLife - October 24th, 2023
- Biobanking Market to Observe Prominent CAGR of 6.10% by 2029 ... - PharmiWeb.com - October 21st, 2023
- TV shows like BBC's Call The Midwife and C4's One Born Every Minute 'are inaccurately depicting childbirth' an - Daily Mail - October 19th, 2023
- Advances in medical and technological research and SCI - Clyde & Co - October 18th, 2023
- Prognostic Value of Hematogones in Patients With Hematopoietic ... - Cureus - October 18th, 2023
- Stem-Cell Therapy: Filling Gaps in Oro-Maxillofacial Region - Cureus - October 18th, 2023
- The neonatal southern white rhinoceros ovary contains oogonia in ... - Nature.com - October 18th, 2023
- OMG: Sperm injury led to rare baby struggle - news.com.au - October 18th, 2023
- Experts Explain how MS Impacts the Eyes and Eye Health - Health Central - October 18th, 2023
Recent Comments